CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 91 enrolled
Drug / intervention
Fluorine F 18 Fluorodopa +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01991977
NCT01991977Phase 2Completed
CompareCT.gov

Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas

Mayo Clinic·interventional·Posted Nov 25, 2013·Updated Oct 20, 2025

In Brief

A Phase 2 clinical trial evaluating Diffusion Weighted Imaging, Fluorine F 18 Fluorodopa, and 5 other interventions for Malignant Glioma. Completed, enrolled 91 participants across 1 site.

Detailed Summary

This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy. Comparing results of diagnostic procedures done before and during radiation therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Glioma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 25, 2013
Enrollment StartDec 1, 2013
Primary CompletionJul 1, 2019
Study CompletionJul 15, 2024
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 12.6 years ago

Interventions

Diffusion Weighted Imagingprocedure

Undergo DTI

Fluorine F 18 Fluorodopadrug

Undergo 18F-DOPA-PET

Intensity-Modulated Radiation Therapyradiation

Undergo IMRT

Perfusion Magnetic Resonance Imagingprocedure

Undergo pMRI

Positron Emission Tomographyprocedure

Undergo 18F-DOPA-PET

Quality-of-Life Assessmentother

Ancillary studies

Temozolomidedrug

Receive temozolomide